Showing results (201-210 of 242) with videos related to
Sort By:
Pageof 25
Molecular Psychiatry|June 27, 2018
Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individualsSamuel Turton, James Fm Myers, Inge Mick, et al.The Journal of Pharmacology and Experimental Therapeutics|May 21, 2013
Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomographyRobert A Comley, Cristian A Salinas, Mark Slifstein, et al.Journal of Psychopharmacology (Oxford, England)|January 17, 2014
Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PETKhanum Ridler, Roger N Gunn, Graham E Searle, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methodsAna M Catafau, Monica Danus, Santiago Bullich, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2014
Phosphodiesterase 10A PET radioligand development program: from pig to humanChristophe Plisson, David Weinzimmer, Steen Jakobsen, et al.JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.Brain Communications|September 8, 2022
Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 PETMohamed A Mohamed, Zhou Zeng, Marta Gennaro, et al.The Lancet. Neurology|June 24, 2019
Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional studyHeather Wilson, George Dervenoulas, Gennaro Pagano, et al.Journal of Medicinal Chemistry|December 8, 2010
Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligandsVictor W Pike, Sabrina Taliani, Talakad G Lohith, et al.Nature Communications|January 16, 2020
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in ratsEllis Chika Onwordi, Els F Halff, Thomas Whitehurst, et al.Pageof 25